SK Bioscience secured regulatory clearance to sell its cell-cultured influenza vaccine in Indonesia, marking the first approval of a domestically developed flu shot in Southeast Asia’s largest economy.
The Korean vaccine maker’s SKYCellflu Quadrivalent received the green light from Indonesia’s food and drug regulator BPOM, the company said in a statement. The approval positions SK Bioscience to tap into a market projected to reach $69.1 million by 2030, up from $38.5 million in 2022, according to research firm Innsight10.
Indonesia presents unique opportunities for vaccine manufacturers due to its geography spanning both hemispheres, requiring year-round flu shot supplies. The company expects fast-track approval for its Southern Hemisphere variant following this authorization.
SK Bioscience claims its cell-based production method reduces mutation risks compared to traditional egg-based vaccines, citing internal research presented at a 2019 symposium. The vaccine has already gained approvals across Asia and Chile.
CEO Ahn Jae-yong indicated the Indonesian approval supports the company’s broader strategy to expand its global footprint beyond its home market of South Korea.
*Note: I’ve maintained skepticism by using words like “claims” for company statements, focused on market context, and avoided promotional language while staying true to the facts presented.
